European Journal of Internal Medicine
Volume 20, Issue 8 , Pages 744-748, December 2009

Prevention of strongyloides hyperinfection syndrome: A rheumatological point of view

  • Mittermayer Santiago

      Affiliations

    • Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil
    • Serviço de Reumatologia do Hospital Santa Izabel (HSI), Salvador, Bahia, Brazil
    • Corresponding Author InformationCorresponding author. Serviço de Reumatologia do Hospital Santa Izabel. Praça Almeida Couto, 500, Nazaré, Salvador, Bahia, CEP 40.050-410, Brazil. Tel.: +71 33265276.
  • ,
  • Bruno Leitão

      Affiliations

    • Serviço de Reumatologia do Hospital Santa Izabel (HSI), Salvador, Bahia, Brazil

Received 29 December 2008; received in revised form 30 August 2009; accepted 4 September 2009. published online 29 September 2009.

Abstract 

Background

Strongyloides stercoralis (S. stercoralis) is a parasite that infects humans and in conditions of immunodeficiency may disseminate, causing the potentially fatal strongyloides hyperinfection syndrome (SHS). The aim of this review was to investigate the literature evidence on the prophylaxis of SHS in immunosuppressed patients with rheumatological disorders.

Material and methods

The MEDLINE database (from 1966 to 2008) was searched using the following terms: “strongyloidiasis”, “disseminated strongyloidiasis”, “Strongyloides stercoralis”, “Strongyloides stercoralis dissemination”, “strongyloides hyperinfection syndrome”, “treatment”, “prophylaxis”, “prevention”, “immunocompromised”, “immunodepression”, “immunosuppressed”, “immunosuppression”, “corticosteroids”, “glucocorticoids”, “lupus erythematosus”, “rheumatoid arthritis”, “rheumatic diseases”. A search of the therapeutic studies using the same set of terms was carried out.

Results

No study on the prophylaxis of SHS restricted to rheumatic immunosuppressed patients was identified. However, two articles have been published on the prophylaxis of strongyloidiasis in other immunosuppressed patients. Additionally, 13 studies dealing with different therapeutical options for strongyloidiasis were identified and presented.

Conclusions

Since there is no evidence on the prophylaxis of SHS in immunosuppressed rheumatic patients, the suggested regimen for that prophylaxis may rely on the results obtained from therapeutical studies. Ivermectin has the best safety profile, lower cost and best efficacy and should be the drug of choice for the prophylaxis of SHS in such patients. Although a definitive prophylactic regimen has not been defined, the option for 200µg/kg/day for 2days, repeated within 2weeks, seems to be a reasonable approach. Such regimen should be repeated every 6months in case of persisting immunosuppression in permanent residents of endemic areas.

Keywords: Strongyloidiasis, Strongyloides stercoralis, Immunosuppression, Strongyloides hyperinfection syndrome, Rheumatic diseases, Prophylaxis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0953-6205(09)00168-X

doi:10.1016/j.ejim.2009.09.001

European Journal of Internal Medicine
Volume 20, Issue 8 , Pages 744-748, December 2009